-

ABIONYX Pharma Announces Its Financial Calendar for the Year 2026

TOULOUSE, France & FULLERTON, Calif.--(BUSINESS WIRE)--Regulatory News:

ABIONYX Pharma, (FR0012616852 - ABNX - PEA PME eligible), a next-generation biopharma company pioneering a new therapeutic era in sepsis and critical care through its proprietary apoA-I–based technology platform, today announces its financial calendar for 2026.

Events

Dates*

Cash position and activity update for Q4 2025

Thursday, February 26, 2026

2025 Full-Year Results

Thursday, March 12, 2026

Cash position and activity update for Q1 2026

Thursday, May 28, 2026

Cash position and activity update for Q2 2026

Thursday, August 27, 2026

2026 Half-Year Results

Thursday, September 24, 2026

Cash position and activity update for Q3 2026

Thursday, November 26, 2026

* indicative dates subject to change

About ABIONYX Pharma

ABIONYX Pharma is a next-generation biopharma company pioneering a new therapeutic era in sepsis and critical care through breakthrough biotherapies that address life-threatening conditions with no effective treatments. Leveraging its proprietary apoA-I–based technology platform, ABIONYX Pharma develops innovative biologics and HDL-derived vectors that target the immune and inflammatory dysregulation underlying sepsis and other severe diseases. With a strong scientific foundation and a growing network of global clinical partners, ABIONYX Pharma aims to redefine the standard of care in sepsis and to bring critical care solutions to patients worldwide.

Contacts

ABIONYX Pharma
infos@abionyx.com

ABIONYX Pharma

BOURSE:ABNX
Release Versions
EnglishFrench

Contacts

ABIONYX Pharma
infos@abionyx.com

More News From ABIONYX Pharma

ABIONYX Pharma and OLON Enter Into Strategic Manufacturing Partnership to Prepare CER-001 Biologic for Regulatory Approval and Commercial Supply

TOULOUSE, France & FULLERTON, Calif.--(BUSINESS WIRE)--Regulatory News: ABIONYX Pharma, (FR0012616852 – ABNX – eligible for the PEA PME), a next-generation biopharmaceutical company developing innovative therapies for sepsis and critical care based on a proprietary apoA-I technology platform, today announced a strategic manufacturing partnership with OLON, a global CDMO, to support the next stage of development and commercialization of CER-001. Preparing CER-001 for the transition from developm...

ABIONYX Pharma: Monthly Statement of Total Voting Rights and Shares Forming the Company’s Share Capital

TOULOUSE, France--(BUSINESS WIRE)--Regulatory News: ABIONYX Pharma (Paris:ABNX): Market: Euronext Paris, Compartment C ISIN code: FR0012616852 Date Number of shares outstanding Total voting rights Total gross (1) Total net (2) September 30, 2026 43,736,415 55,932,572 55,671,329 (1) The total number of gross (or “theoretical”) voting rights is used as the basis for calculating threshold crossings. In accordance with Article 223-11 of the AMF General Regulations, this number is calculated on the...

ABIONYX Pharma Announces the Settlement of an Anticipated Amortization Payment in Accordance With the Terms of Its Bonds Financing Agreement

TOULOUSE, France & FULLERTON, Calif.--(BUSINESS WIRE)--Regulatory News: ABIONYX Pharma (FR0012616852 – ABNX – eligible for PEA-PME) (“Abionyx” or the “Company”), a next-generation biopharmaceutical company developing innovative therapies in sepsis and critical care based on its exclusive apoA-I technology platform, today announces (i) a partial repayment of the principal amount of the bonds subscribed by Fenja Capital II A/S (“Fenja”) and (ii) consequently, the pricing of a EUR 0.52 Million res...
Back to Newsroom